# CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

> **NCT00211939** · PHASE4 · COMPLETED · sponsor: **Nabi Biopharmaceuticals** · enrollment: 203 (actual)

## Conditions studied

- Calcinosis
- Arteriosclerosis
- Hyperparathyroidism, Secondary

## Interventions

- **DRUG:** calcium acetate
- **DRUG:** sevelamer
- **DRUG:** atorvastatin

## Key facts

- **NCT ID:** NCT00211939
- **Lead sponsor:** Nabi Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-12
- **Final completion:** 2007-03
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2008-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211939, "CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00211939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*